Legal Representation
Attorney
Scott W. Smilie
USPTO Deadlines
Next Deadline
45 days remaining
NOA E-Mailed - SOU Required
Due Date
February 13, 2026
Extension Available
Until August 13, 2026
Application History
35 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 12, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 11, 2025 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Aug 11, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 11, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Aug 11, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 29, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 29, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 29, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 13, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jun 18, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jun 18, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| May 29, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| May 16, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 16, 2024 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 16, 2024 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 16, 2024 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| May 16, 2024 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| May 14, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 14, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 14, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 10, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 10, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 10, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 8, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 8, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 8, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Mar 4, 2024 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Mar 4, 2024 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Dec 5, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Dec 5, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Dec 5, 2023 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Dec 4, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Mar 10, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 9, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 035
(Based on Intent to Use) Charitable services, namely, promoting public awareness of the need for access to pharmaceuticals; Charitable services, namely promoting public awareness of the need for equitable access to generic drugs for other diseases
Class 036
(Based on Use in Commerce) Charitable fundraising services
First Use Anywhere:
20220900
First Use in Commerce:
20220900
Class 042
(Based on Intent to Use) Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consulting services in the field of pharmaceutical research; Testing of pharmaceuticals; Laboratory research services relating to pharmaceuticals; and using data to identify potential other uses for generic drugs; (Based on Use in Commerce) Charitable services, namely, conducting research, studies and trials for others on alternative uses for pharmaceuticals
First Use Anywhere:
20220900
First Use in Commerce:
20220900
Classification
International Classes
035
036
042
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"CURE"